Cargando…
Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax(®)) in children
BACKGROUND: Grass pollen-induced rhinoconjunctivitis is a common allergic respiratory disorder affecting over 20% of the UK population in terms of quality of life and sleep, work, and school patterns. The SQ-standardized grass allergy immunotherapy tablet (AIT) has been demonstrated as a disease-mod...
Autores principales: | Ronaldson, Sarah, Taylor, Matthew, Bech, Peter G, Shenton, Ruth, Bufe, Albrecht |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011810/ https://www.ncbi.nlm.nih.gov/pubmed/24812522 http://dx.doi.org/10.2147/CEOR.S44079 |
Ejemplares similares
-
Treatment of grass pollen allergy: focus on a standardized grass allergen extract – Grazax(®)
por: Calderón, Moisés, et al.
Publicado: (2008) -
Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study
por: Reiber, Rainer, et al.
Publicado: (2016) -
Health-Related Quality of Life During Routine Treatment with the SQ-Standardised Grass Allergy Immunotherapy Tablet: A Non-Interventional Observational Study
por: Horn, Andreas, et al.
Publicado: (2016) -
Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study
por: Schwab, Jan-Alexander, et al.
Publicado: (2018) -
Critical appraisal of Timothy grass pollen extract GRAZAX(®) in the management of allergic rhinitis
por: Scaparrotta, Alessandra, et al.
Publicado: (2015)